From: Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Characteristic | Physicians, n (%) (N = 136a) |
---|---|
Clinician status | |
Resident/Trainee | 19 (14.0) |
Consultant | 115 (84.6) |
Other/Missing | 2 (1.5) |
Country | |
UK | 43 (31.6) |
Germany | 35 (25.7) |
Austria | 2 (1.5) |
France | 23 (16.9) |
Spain | 30 (22.1) |
Sweden | 3 (2.2) |
Setting | |
NHS only | 37 (27.2) |
Private practice only | 24 (17.6) |
Both NHS and private practice | 6 (4.4) |
University clinic | 44 (32.4) |
Other clinic | 25 (18.4) |
In your opinion, does your country have a history of large scale use of first generation LAI prescriptions (> 20% of all antipsychotic prescriptions)? | |
Yes, and this is still the case | 30 (22.1) |
Yes, but this number has dropped | 80 (58.8) |
Not historically, but this is now the case | 8 (5.9) |
No, this was never the case | 18 (13.2) |
Has your rate of prescribing LAI antipsychotics for schizophrenia changed over the last 5 years? | |
Marked decrease | 2 (1.5) |
Slight decrease | 16 (11.8) |
Unchanged | 37 (27.2) |
Slight increase | 55 (40.4) |
Marked increase | 26 (19.1) |
How would you rate your level of clinical experience with the use of antipsychotics LAIs for schizophrenia? | |
No experience | 1 (0.7) |
Minimal experience | 2 (1.5) |
Somewhat experienced | 28 (20.6) |
Very experienced | 105 (77.2) |